These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 22890794)

  • 1. HPV vaccination and cervical cancer.
    Szarewski A
    Curr Oncol Rep; 2012 Dec; 14(6):559-67. PubMed ID: 22890794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT; Castellsagué X; Garland SM
    Vaccine; 2012 Nov; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
    BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
    Drolet M; Bénard É; Boily MC; Ali H; Baandrup L; Bauer H; Beddows S; Brisson J; Brotherton JM; Cummings T; Donovan B; Fairley CK; Flagg EW; Johnson AM; Kahn JA; Kavanagh K; Kjaer SK; Kliewer EV; Lemieux-Mellouki P; Markowitz L; Mboup A; Mesher D; Niccolai L; Oliphant J; Pollock KG; Soldan K; Sonnenberg P; Tabrizi SN; Tanton C; Brisson M
    Lancet Infect Dis; 2015 May; 15(5):565-80. PubMed ID: 25744474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL; Joura EA
    Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diseases caused by human papilloma viruses].
    Zollner U; Schwarz TF
    Dtsch Med Wochenschr; 2011 May; 136(20):1067-72. PubMed ID: 21560109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the new HPV vaccines in clinical practice.
    Widdice LE; Kahn JA
    Cleve Clin J Med; 2006 Oct; 73(10):929-35. PubMed ID: 17044318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
    Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
    Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
    McCormack PL
    Drugs; 2014 Jul; 74(11):1253-83. PubMed ID: 25022951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical approval: Trials of an anticancer jab.
    Clayton J
    Nature; 2012 Aug; 488(7413):S4-6. PubMed ID: 22932438
    [No Abstract]   [Full Text] [Related]  

  • 15. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
    Schiller JT; Castellsagué X; Villa LL; Hildesheim A
    Vaccine; 2008 Aug; 26 Suppl 10(Suppl 10):K53-61. PubMed ID: 18847557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
    Szarewski A
    Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Currently approved prophylactic HPV vaccines.
    Harper DM
    Expert Rev Vaccines; 2009 Dec; 8(12):1663-79. PubMed ID: 19943762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
    Khaliq SA; Shyum Naqvi SB; Fatima A
    Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vaccination against human papilloma virus and cervical cancer].
    Kidon MI; Shechter E; Toubi E
    Harefuah; 2011 Jan; 150(1):33-6, 68. PubMed ID: 21449154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic HPV vaccines.
    Szarewski A
    Eur J Gynaecol Oncol; 2007; 28(3):165-9. PubMed ID: 17624079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.